We have developed a technology for improving avidity by making bivalent, trivalent, or tetravalent recombinant polypeptides. We designed tripartite proteins consisting of the Fab fragment of an antibody fused with a hinge derived from human immunoglobulin D that was further linked to polymerization domains derived from human coiled-coil proteins. We report here on the application of this method with a Fab domain directed against the major human rhinovirus receptor, intercellular adhesion molecule 1 (ICAM-1). Multivalent anti-ICAM-1 molecules were produced in bacteria and purified as soluble preassembled homogeneous proteins at high yield. These proteins successfully blocked rhinovirus infection in vitro, with the efficiency increasing from monomer to dimer, trimer, and tetramer. The diminished dissociation rate of these multivalent antibodies and their improved efficacy in preventing rhinovirus infection provide a foundation for producing prophylactic and therapeutic molecules against human rhinovirus, the causative agent of the majority of common colds.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC153330 | PMC |
| http://dx.doi.org/10.1128/AAC.47.5.1503-1508.2003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of and Alkylamides on Respiratory Virus Replication and IL-8 Expression In Vitro.
Molecules
January 2025
Ric Scalzo Institute for Botanical Research, Sonoran University of Health Sciences, Tempe, AZ 85282, USA.
is a perennial medicinal herb with important immunomodulatory and anti-inflammatory properties, especially purported for the alleviation of cold and flu symptoms. Different classes of secondary metabolites of the plant, such as alkylamides, caffeic acid derivatives, polysaccharides, flavonoids, and glycoproteins, are believed to be biologically and pharmacologically active. Although previous research suggests that the alkylamides present in may be responsible for reducing the symptoms associated with the common cold or flu through their immunomodulatory activity, the roles of specific alkylamides and their targets (i.
View Article and Find Full Text PDFChanges in infant respiratory pathogens pre-, during, and post-COVID-19 non-pharmacological interventions in Beijing.
Ital J Pediatr
January 2025
Department of Neonatology, Children's Hospital, Capital Institute of Pediatrics, Beijing, 100020, China.
Background: To explore the effect of non-pharmacological interventions (NPIs) on respiratory pathogen profiles among hospitalized infants aged 0-3 months in Beijing during the coronavirus disease 2019 (COVID-19) pandemic.
Methods: Respiratory specimens were collected from 1,184 infants aged 0-3 months who were hospitalized for acute respiratory infection at the Children's Hospital affiliated with the Capital Institute of Pediatrics from January 2018 to December 2023. The data were divided into three groups-the pre-epidemic (January 2018 to December 2019), epidemic prevention and control (January 2020 to December 2022), and post-epidemic (January 2023 to December 2023) groups-based on the outbreak of COVID-19 and the implementation and termination of NPIs.
Respiratory virus detections in children presenting to an Australian paediatric referral hospital pre-COVID-19 pandemic, January 2014 to December 2019.
PLoS One
January 2025
Sydney Medical School, University of Sydney, Sydney, New South Wales (NSW), Australia.
Acute respiratory infections cause significant paediatric morbidity, but for pathogens other than influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, systematic monitoring is not commonly performed. This retrospective analysis of six years of routinely collected respiratory pathogen multiplex PCR testing at a major paediatric hospital in New South Wales Australia, describes the epidemiology, year-round seasonality, and co-detection patterns of 15 viral respiratory pathogens. 32,599 respiratory samples from children aged under 16 years were analysed.
View Article and Find Full Text PDFDesigning a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach.
Front Immunol
January 2025
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Human rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap by employing immunoinformatics techniques for the design of a multi-epitope-based vaccine against HRV-C.
View Article and Find Full Text PDFA new epidemic wave of Bordetella pertussis in paediatric population: impact and role of co-infections in pertussis disease.
Ital J Pediatr
January 2025
Unit of Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, IRCSS, Rome, 00165, Italy.
Background: In recent months, Bordetella pertussis has reappeared after maintaining a low rate for many years. Although pertussis is usually characterized by a favorable course, several factors can contribute to the severity of the disease, such as mixed respiratory infections. In this study, we evaluate B.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!